Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Kelemen, Linda E ^a,b   Brenton, James D ^c,d,e   Parkinson, Christine ^c   Whitaker, Hayley C ^c   Piskorz, Anna M ^c   Csizmadi, Ilona ^a,b   Robson, Paula J ^a,f  

^a ALBERTA HEALTH SERVICES   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Queen Mary University of London and Barts NIHR BRC NHS Trust National Institute for Health and Care Research   (United Kingdom)

^e Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FOLATE RECEPTOR 1; RETINOL; FOLR1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; LIFESTYLE MODIFICATION; MALE; MOLECULAR DYNAMICS; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREND STUDY; VITAMIN INTAKE; BLOOD; DIET; LIFESTYLE; MIDDLE AGED; NORMAL HUMAN; PREGNANCY; REFERENCE VALUE; REPRODUCTION;

ADULT; AGED; COHORT STUDIES; DIET; FEMALE; FOLATE RECEPTOR 1; HEALTHY VOLUNTEERS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PREGNANCY; REFERENCE VALUES; REPRODUCTION;

EID: 84901503808     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096542     Document Type: Article

References (39)

1. Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: Cause, consequence or innocent bystander? Int J Cancer 119: 243-250.
2. Henderson GB (1990) Folate-binding proteins. Annu Rev Nutr 10: 319-335.
3. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD (2013) Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol 131: 493-498.
4. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, et al. (2013) PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol 31: 4400-4406.
5. Leamon CP, Reddy JA (2004) Folate-targeted chemotherapy. Adv Drug Deliv Rev 56: 1127-1141. (Pubitemid 38496512)
6. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, et al. (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 17: 1315-1319.
7. He W, Kularatne SA, Kalli KR, Prendergast FG, Amato RJ, et al. (2008) Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer 123: 1968-1973.
8. Xia W, Low PS (2010) Folate-targeted therapies for cancer. J Med Chem 53: 6811-6824.
9. Kelley KM, Rowan BG, Ratnam M (2003) Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res 63: 2820-2828. (Pubitemid 36667153)
10. Rochman H, Selhub J, Karrison T (1985) Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev 8: 71-75.
11. Kane MA, Elwood PC, Portillo RM, Antony AC, Najfeld V, et al. (1988) Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 81: 1398-1406.
12. Matsue H, Rothberg KG, Takashima A, Kamen BA, Anderson RG, et al. (1992) Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc Natl Acad Sci U S A 89: 6006-6009.
13. Luhrs CA, Raskin CA, Durbin R, Wu B, Sadasivan E, et al. (1992) Transfection of a glycosylated phosphatidylinositol-anchored folate-binding protein complementary DNA provides cells with the ability to survive in low folate medium. J Clin Invest 90: 840-847.
14. Tran T, Shatnawi A, Zheng X, Kelley KM, Ratnam M (2005) Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Res 65: 4431-4441. (Pubitemid 40775683)
15. Bolton JA, Wood SA, Kennedy D, Don RH, Mattick JS (1999) Retinoic acid-dependent upregulation of mouse folate receptor-alpha expression in embryonic stem cells, and conservation of alternative splicing patterns. Gene 230: 215-224. (Pubitemid 29195888)
16. Kelemen LE, Sellers TA, Keeney GL, Lingle WL (2005) Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 2168-2172. (Pubitemid 41603263)
17. Food standards: amendment of the standards of identity for enriched grain products to require addition of folic acid. Final rule. 1996. Fed Regist 61: 8781-8797.
18. Health Canada (November 25, 1998) Folic acid fortification in Canada. Canada Gazette Part II 132 (24): 3026-3040.
19. Food standards Australia New Zealand. Final assessment report. Proposal P295. Consideration of mandatory fortification with folic acid. http://wwwfoodstandardsgovau/standardsdevelopment/. Accessed: 2006 October 4.
20. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, et al. (2004) Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160: 339-349. (Pubitemid 39045265)
21. Luhrs CA, Pitiranggon P, da Costa M, Rothenberg SP, Slomiany BL, et al. (1987) Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation. Proc Natl Acad Sci U S A 84: 6546-6549. (Pubitemid 18002817)
22. Campbell IG, Jones TA, Foulkes WD, Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51: 5329-5338.
23. Brown D, Waneck GL (1992) Glycosyl-phosphatidylinositol-anchored membrane proteins. J Am Soc Nephrol 3: 895-906.
24. Waxman S, Schreiber C (1973) Measurement of serum folate levels and serum folic acid-binding protein by 3H-PGA radioassay. Blood 42: 281-290.
25. Da Costa M, Rothenberg SP (1974) Appearance of a folate binder in leukocytes and serum of women who are pregnant or taking oral contraceptives. J Lab Clin Med 83: 207-214.
26. Colman N, Herbert V (1976) Total folate binding capacity of normal human plasma, and variations in uremia, cirrhosis, and pregnancy. Blood 48: 911-921.
27. Markkanen T, Virtanen S, Pajula RL, Himanen P (1974) Hormonal dependence of folic acid protein binding in human serum. Int J Vitam Nutr Res 44: 81-94.
28. (1982) Serum folate binders are not correlated to folate nutritional status. Nutr Rev 40: 234-235.
29. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, et al. (2009) Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 4: e6292.
30. Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V (2013) Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. Clin Biochem 46: 1462-1468.
31. O'Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, et al. (2013) Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res 6: 29.
32. Bryant H, Robson PJ, Ullman R, Friedenreich C, Dawe U (2006) Population-based cohort development in Alberta, Canada: a feasibility study. Chronic Dis Can 27: 51-59. (Pubitemid 44784428)
33. Csizmadi I, Kahle L, Ullman R, Dawe U, Zimmerman TP, et al. (2007) Adaptation and evaluation of the National Cancer Institute's Diet History Questionnaire and nutrient database for Canadian populations. Public Health Nutr 10: 88-96. (Pubitemid 46682346)
34. Xu Y, Wang T, Tang R, Tang S (2010) All-trans retinoic acid is capable of inducing folate receptor beta expression in KG-1 cells. Tumour Biol 31: 589-595.
35. Li H, Lu Y, Piao L, Wu J, Liu S, et al. (2010) Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int J Pharm 402: 57-63.
36. Healey CS, Dunning AM, Durocher F, Teare D, Pharoah PD, et al. (2000) Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21: 189-193. (Pubitemid 30098702)
37. Institute of Medicine (2001) Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington, DC: National Academy Press.
38. Saikawa Y, Price K, Hance KW, Chen TY, Elwood PC (1995) Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. Biochemistry 34: 9951-9961.
39. Elwood PC, Nachmanoff K, Saikawa Y, Page ST, Pacheco P, et al. (1997) The divergent 59 termini of the alpha human folate receptor (hFR) mRNAs originate from two tissue-specific promoters and alternative splicing: characterization of the alpha hFR gene structure. Biochemistry 36: 1467-1478. (Pubitemid 27074971)